Search the category and the same sentence keeps coming back: lion's mane is said to be proven to raise nerve growth factor. No human trial has measured nerve growth factor in a human brain in response to eating the mushroom. This is what the laboratory work shows, what the small human trials show, and the distance between the two.
Nerve growth factor started on a bedroom table
Barred from academic work by Italy's 1938 racial laws, Rita Levi-Montalcini built a laboratory in her bedroom and continued studying chick embryos with hand-ground instruments.
The work she began there led, with Stanley Cohen, to the isolation of a protein that made nerve fibres grow toward it. They named it nerve growth factor and shared the 1986 Nobel Prize in Physiology or Medicine for it.
NGF is now one of the best-described signalling proteins in neuroscience, which is why it is such a useful word to put on a package.
The fact that constrains every claim made about it
NGF is a protein of roughly 26 kilodaltons. Proteins that size do not cross the blood–brain barrier, and they are digested into fragments if swallowed.
So no oral product delivers NGF. Nothing on the shelf could, and any product implying otherwise is describing something physically impossible.
The actual claim has to be indirect: that a compound small enough to be absorbed reaches nerve tissue and prompts the cells there to make more NGF themselves. That is a much longer chain, and the argument can thin out at any link.
Where the lion's mane story comes from
In the early 1990s Hirokazu Kawagishi's group in Japan isolated a family of compounds from the fruiting body of Hericium erinaceus and named them hericenones (Tetrahedron Letters; chemical isolation studies).
A few years later the same line of work described a second family, the erinacines, from the mycelium, reported as strong stimulators of NGF synthesis (Tetrahedron Letters, 1994).
Both findings are real chemistry and both are now over thirty years old. The entire NGF marketing edifice rests on them.
What "stimulates NGF synthesis" meant in those papers
Compounds were applied directly to cultured cells — astrocyte-derived cell lines in a dish — at concentrations the experimenter chose, and NGF output was measured.
That design skips four things a swallowed capsule cannot skip: digestion, absorption across the gut wall, first-pass metabolism in the liver, and the blood–brain barrier.
A dish is not a person, and a positive result in one is a reason to run a trial rather than a claim about anybody.
The awkward fact about which part carries what
The compound with the strongest animal data is not in the fruiting body
Hericenones are described from the fruiting body; erinacines from the mycelium. The stronger NGF-stimulation results in the literature involve erinacine A, which is the mycelial compound.
That is genuinely inconvenient for any product made from fruiting body only, and it is stated here rather than left out.
Why the human trials still sit on the fruiting-body side
Almost all the human trials used fruiting-body preparations, so the clinical record such as it is sits on that side. Mycelium sold in the United States is typically grown on grain and harvested with the substrate attached, which makes much of the finished powder starch rather than mushroom.
The distinction, and how to see it on a panel, is in fruiting body versus mycelium. The measurement that separates a real extract from grain flour is the beta-glucan figure, covered in the one number to look for on a mushroom supplement.
The animal work
A mouse study in an amyloid-induced model reported smaller learning and memory deficits in animals given Hericium erinaceus (Mori et al., Biomedical Research, 2011; mouse study).
Rats with a crush injury to the peroneal nerve recovered function faster on an aqueous extract than controls (Wong et al., Evidence-Based Complementary and Alternative Medicine, 2011; rat study).
Peripheral nerve regeneration is the more interesting of the two, because it does not require anything to cross the blood–brain barrier. It is also a rat.
The human trials, all of them small
The one everybody cites
Japanese adults aged 50 to 80 with mild cognitive impairment took 3 g a day of dried fruiting-body powder for sixteen weeks. Cognitive scale scores rose against placebo. Four weeks after stopping, the scores fell back (Mori et al., Phytotherapy Research, 2009; n=30, randomised double-blind).
Fifteen people per arm, with a diagnosis, on a dose of powder far above what a capsule serving typically delivers. The discontinuation result is the most useful thing in it and is almost never quoted.
The one in healthy adults
Healthy Japanese adults took about 3.2 g a day for twelve weeks, with improvement reported on one cognitive screening instrument, while the other two showed no effect (Saitsu et al., Biomedical Research, 2019; n=31).
The one in mild Alzheimer's disease
Erinacine A-enriched mycelium at 1,050 mg a day was tested for 49 weeks in a pilot of 49 people with mild Alzheimer's disease (Li et al., Frontiers in Aging Neuroscience, 2020; n=49 enrolled, pilot study). A pilot that size cannot establish anything, and it is listed here for completeness.
The one in young healthy adults, which is mostly negative
Adults aged 18 to 45 took 1.8 g a day for 28 days. Performance on a speeded interference task was faster an hour after a single dose. At day 28 there was a trend toward lower subjective stress that did not reach significance, and the chronic cognitive outcomes largely did not separate from placebo (Docherty et al., Nutrients, 2023; n=41, double-blind parallel groups).
The trials, side by side
| Study | Who | Preparation and dose | Duration | Result |
|---|---|---|---|---|
| Mori et al., 2009 | n=30, aged 50–80, mild cognitive impairment | Dried fruiting body, 3 g/day | 16 weeks | Scores rose; fell back four weeks after stopping |
| Saitsu et al., 2019 | n=31, healthy adults | Fruiting body, about 3.2 g/day | 12 weeks | Improvement on a screening instrument |
| Li et al., 2020 | n=49 enrolled, mild Alzheimer's disease | Erinacine A-enriched mycelium, 1,050 mg/day | 49 weeks | Pilot study; too small to establish anything |
| Docherty et al., 2023 | n=41, healthy adults aged 18–45 | Fruiting body, 1.8 g/day | 28 days, plus an acute dose | Acute speeding on one task; chronic outcomes largely null |
The gap, stated plainly
Not one of those trials measured nerve growth factor in the human brain, because doing so means sampling brain tissue or spinal fluid, which nobody would consent to for a mushroom study.
The NGF evidence is in cell cultures and rodents. The human evidence is a handful of small trials measuring cognitive test scores, in populations that mostly had a diagnosis. Those are two separate claims, and the marketing sentence welds them together.
The dose problem, including ours
The fruiting-body trials used roughly 1.8 to 3.2 g a day of dried mushroom powder. A few hundred milligrams of concentrated extract is not the same thing, and the arithmetic that appears to reconcile them — milligrams multiplied by an extraction ratio equals grams — is a manufacturing ratio, not a demonstration of equivalence.
An extraction ratio describes how much raw material went in. It does not certify that the compounds that mattered came through in proportion, which is why the beta-glucan percentage and a lot-specific certificate carry more weight than the ratio does. Both are covered in what a certificate of analysis actually tells you.
This applies to our own label as much as anyone's, and it is the reason the extract ratio is not the number we put forward.
Why this ingredient in particular gets over-claimed
Because the mechanism has a famous name attached to it, the chemistry is genuinely real, and nobody selling it has to prove the last step.
"Supports NGF" is unfalsifiable at the point of sale. A beta-glucan percentage on a certificate is not, which is why a transparency claim is worth more than a mechanism claim — the argument made at length in what a proprietary blend hides.
What a buyer can check
Four things, all printable and all verifiable: the Latin species name, the part used, the beta-glucan percentage, and whether a lot-specific certificate exists. Locating them takes about a minute using the sequence in how to read a Supplement Facts panel in about sixty seconds.
None of those four says the product works. They say what is in it, which is the only question a label is competent to answer.
Where we stand
Weal Focus contains 400 mg of lion's mane extract from 100% fruiting body, standardised to at least 25% beta-glucans — the figure our purchasing specification sets and the pouch prints.
That is a statement about composition. It is not a claim that the product raises nerve growth factor in anybody, and this page exists because that claim is made constantly and cannot presently be supported. The question of how long a supplement takes to do anything at all is taken up in how long a supplement actually takes.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Sources for the claims and figures on this page, with the population studied in each, are on our citations page.